Drug Profile
Goserelin prolonged-release - Ambrilia Biopharma
Latest Information Update: 25 Nov 2021
Price :
$50
*
At a glance
- Originator Ambrilia Biopharma
- Class Antineoplastics; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
- Mechanism of Action Gonadotropin releasing hormone stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Prostate cancer
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 09 Jul 2013 Discontinued - Phase-I/II for Prostate cancer prior to 9 July 2013 (Parenteral)
- 13 Mar 2009 Goserelin is available for licensing in Europe and Japan (http://www.ambrilia.com)